Chronic Obstructive Pulmonary Disease, Hyperglycemia
Conditions
Keywords
Chronic Obstructive Pulmonary Disease, Corticosteroid induced hyperglycaemia, Insulin
Brief summary
The purpose of this study is to determine the effect of preventing hyperglycaemia in patients admitted to hospital with acute exacerbations of chronic pulmonary disease.
Detailed description
Hyperglycaemia is associated with increased morbidity and mortality in patients admitted to hospital with acute critical illness, myocardial infarction and stroke. Moreover patients with hyperglycaemia have a significantly longer hospital stay, higher rates of ICU admission, increased in-hospital mortality and are more likely to require transfer to a nursing home. Recently, interventional studies have linked reversal of hyperglycaemia to better clinical outcomes especially in acute myocardial infarction, cardiac surgery and in critically ill patients. In England and Wales, it is estimated that the number of people with COPD is approaching 1.5 million. The morbidity and economic costs associated with the condition are extremely high with approximately 10% of all acute medical admissions caused by exacerbations of the underlying condition. As a corollary about 15% of patients with COPD need admission to hospital each year. Acute hyperglycaemia is common among patients admitted with acute exacerbations of COPD. The reasons for this are likely to be multi-factorial including an association between COPD and increased risk of developing diabetes at least in women, the elderly nature of the two populations and the use of glucocorticoids which markedly increases the risk of hyperglycaemia. Admission hyperglycaemia (\>11 mmol/l) also appears to predict increased morbidity for patients with COPD admitted to intensive care. The trial will be a randomised trial of comparison of usual treatment vs intensive insulin treatment for patients with COPD who may or may not have diabetes. Patients will take part in the trial for the first 5 days during their hospital stay.
Interventions
PROCEDUREBlood glucose monitoring
Regular pre and post meal blood glucose monitoring.
DRUGInsulin Glulisine
Sub cutaneous injection given twice daily for 3 days. Dosage titrated to body mass index and body weight (BMI \< 30 = 0.1 unit/kg. BMI \> 30 = 0.2 unit/kg)
Sponsors
Sanofi
The Royal Bournemouth Hospital
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who are NOT diabetic, admitted with COPD who are likely to be prescribed corticosteroids as part of usual care with an admission glucose level (before steroids) between 6.1 and 11.1 mmol/l.
Exclusion criteria
* Patients with diabetes mellitus * Patients who are nil by mouth. * Patients with severe co-morbid disease with an anticipated life expectancy of \< 6 months. * Patients who are unable to provide informed consent. * Age \<18 years.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of re-admission to hospital within 90 days. | 90 days after discharged from hospital |
Secondary
| Measure | Time frame |
|---|---|
| In-patient mortality | look at cause death. for statistical purpose oct 2009 |
| Spirometry at baseline, day 3 and prior to discharge | oct 2009 |
| Achieved glucose levels | oct 2009 |
| Length of stay | oct 2009 |
| Frequency of positive sputum cultures | oct 2009 |
| Change in CRP and IL-6 levels between baseline and day 5 | oct 2009 |
| Hypoglycaemic events (<4 mmol/l with or without symptoms) | instigate hypoglycaemia protocol at time. for statistical purpose oct 2009. |
Countries
United Kingdom
Outcome results
None listed